<?xml version='1.0' encoding='utf-8'?>
<document id="26320364"><sentence text="[Which place for direct oral anticoagulants in routine hospital medical practice?]." /><sentence text="More than one million patients received an oral anticoagulant treatment in France" /><sentence text=" This medication is the first aetiology of iatrogenic events" /><sentence text=" Recently, direct oral anticoagulant (DOA) provided efficacy and safety in the treatment of atrial fibrillation and venous thromboembolic events" /><sentence text=" Given the growing increase in the prescription of these molecules, with many advantages but also disadvantages, it seemed interesting to assess in routine hospital medical practice, the proportion of patients for which the initiation of AOD could be safe" /><sentence text="" /><sentence text="This prospective, observational study was conducted in the department of internal medicine from October 2012 and September 2013" /><sentence text=" All inpatients receiving oral anticoagulant treatment have been included" /><sentence text=" Demographic data, indication of anticoagulant treatment, contraindications and interactions have been reported" /><sentence text=" From these information, we have established the percentage of patients who could benefit from DOA safely and securely" /><sentence text="" /><sentence text="Two hundred and ninety inpatients were included with a mean age of 76" /><sentence text="3Â±15" /><sentence text="2 years old" /><sentence text=" Atrial fibrillation and thromboembolic venous disease were the most prevalent indications of anticoagulant treatments (67" /><sentence text="2% and 22" /><sentence text="4% of cases respectively)" /><sentence text=" Among all patients, 260 had an indication of DOA (89" /><sentence text="7%), authorized by the French National health agency" /><sentence text=" Eighty percent had both indication and no contraindication for DOA" /><sentence text=" However, only 53" /><sentence text="1% of patients neither had drug-drug interaction" /><sentence text=" Main contraindications were severe renal failure (clearance&lt;30mL/min) in 10" /><sentence text="7% of cases, and recent history of gastric ulcer in 15" /><sentence text="3% of cases" /><sentence text=" The most frequent interactions with DOA were antiplatelet agent (14" /><sentence text="5%) and amiodarone (11"><entity charOffset="8-18" id="DDI-PubMed.26320364.s27.e0" text="amiodarone" /></sentence><sentence text="6%)" /><sentence text=" Almost two thirds of inpatients (65" /><sentence text="1%) had at least one drug-drug interaction with VKA" /><sentence text="" /><sentence text="These results, coming from &quot;real life&quot;, provide that only 53" /><sentence text="1% of inpatients under anticoagulants could receive DOA safely" /><sentence text=" Caution is warranted, and VKA still have a preponderant role among anticoagulant drugs" /><sentence text="" /></document>